Viatris partners with NVIDIA to accelerate AI-driven drug discovery by optimizing the Proteina Complexa model for designing novel therapeutics targeting muscle atrophy.
This collaboration signifies a significant advancement in pharmaceutical R&D by integrating cutting-edge AI from NVIDIA with Viatris's established 'wet-dry closed-loop' drug discovery platform. It promises to accelerate the identification and design of novel therapeutic candidates, potentially leading to faster development of treatments for conditions like muscle atrophy and reducing the cost and time associated with traditional drug discovery processes.
Viatris and NVIDIA are collaborating to enhance AI-driven drug discovery.
The partnership focuses on optimizing the Proteina Complexa model for mini-binder design targeting ActRIIA.
This initiative leverages NVIDIA's technology to accelerate the discovery of novel therapeutics.
The press release originates from China, highlighting the growing importance of AI in drug discovery within the Asia-Pacific region and globally. Viatris, a global CRO, is actively participating in this trend.
This initiative leverages NVIDIA's technology to accelerate the discovery of novel therapeutics.
The collaboration aims to reduce drug discovery timelines and costs through AI integration.
Sign in to save notes on signals.
Sign In